GLPwatch
Pioneering oral peptide therapy for patients with type 2 diabetes.
Lancet Diabetes Endocrinol · 2019
Last updated 2026-09-22| Journal | Lancet Diabetes Endocrinol, 2019 |
|---|---|
| Citations | 11 |
| Relative citation ratio | 0.45 |
| NIH percentile | 27 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes |
Full record and abstract on PubMed 31189516 ↗